Invention Grant
- Patent Title: Bromodomain inhibitors
-
Application No.: US17139963Application Date: 2020-12-31
-
Publication No.: US11884680B2Publication Date: 2024-01-30
- Inventor: Amogh Boloor
- Applicant: CELGENE QUANTICEL RESEARCH, INC.
- Applicant Address: US CA San Diego
- Assignee: Celgene Quanticel Research, Inc.
- Current Assignee: Celgene Quanticel Research, Inc.
- Current Assignee Address: US CA San Diego
- Agency: Foley & Lardner LLP
- The original application number of the division: US15990576 2018.05.25
- Main IPC: C07D498/04
- IPC: C07D498/04 ; C07D217/24 ; C07D413/04 ; C07D401/04 ; C07D471/04 ; C07D405/04 ; C07D487/04 ; C07D211/94 ; C07D401/14 ; C07D213/64 ; C07D213/73 ; C07D213/74 ; C07D237/14 ; C07D239/54 ; C07D239/56 ; C07D241/20 ; C07D403/04 ; C07D405/12 ; C07D409/04 ; C07D413/06 ; C07D417/14 ; C07D491/048 ; C07D495/04 ; C07D213/69 ; C07D213/70 ; C07D401/12 ; C07D405/06
Abstract:
The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.
Public/Granted literature
- US20220315601A1 BROMODOMAIN INHIBITORS Public/Granted day:2022-10-06
Information query
